Paper37101772
Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making?
Soria F and 16 others. Eur Urol Open Sci, 2023. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making? Papers, record 37101772. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37101772
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guérin: Implications for Decision-making?
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References24
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31834509 | Imaging of sarcopenia: old evidence and new insights. | Eur Radiol | 2020 | https://conductscience.org/library/papers/31834509 | PubMed |
| 2 | 29289518 | The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy. | Clin Genitourin Cancer | 2018 | https://conductscience.org/library/papers/29289518 | PubMed |
| 3 | 21296615 | Definition and classification of cancer cachexia: an international consensus. | Lancet Oncol | 2011 | https://conductscience.org/library/papers/21296615 | PubMed |
| 4 | 27104110 | Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. | J Cachexia Sarcopenia Muscle | 2016 | https://conductscience.org/library/papers/27104110 | PubMed |
| 5 | 24840856 | Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. | Cancer | 2014 | https://conductscience.org/library/papers/24840856 | PubMed |
| 6 | 21782482 | Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? | Urol Oncol | 2013 | https://conductscience.org/library/papers/21782482 | PubMed |
| 7 | 34511303 | European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). | Eur Urol | 2022 | https://conductscience.org/library/papers/34511303 | PubMed |
| 8 | 20392703 | Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. | Age Ageing | 2010 | https://conductscience.org/library/papers/20392703 | PubMed |
| 9 | 25552207 | Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. | World J Urol | 2015 | https://conductscience.org/library/papers/25552207 | PubMed |
| 10 | 33419683 | European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. | Eur Urol | 2021 | https://conductscience.org/library/papers/33419683 | PubMed |
| 11 | 32360052 | European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. | Eur Urol | 2021 | https://conductscience.org/library/papers/32360052 | PubMed |
| 12 | 26123787 | Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. | Dis Esophagus | 2016 | https://conductscience.org/library/papers/26123787 | PubMed |
| 13 | 30259123 | Molecular markers in bladder cancer. | World J Urol | 2019 | https://conductscience.org/library/papers/30259123 | PubMed |
| 14 | 34437899 | Psoas Muscle Mass can Predict Postsurgical Outcomes in Patients Who Undergo Radical Cystectomy and Urinary Diversion Reconstruction. | Urology | 2021 | https://conductscience.org/library/papers/34437899 | PubMed |
| 15 | 29520591 | Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer. | World J Urol | 2018 | https://conductscience.org/library/papers/29520591 | PubMed |
| 16 | 25431236 | Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. | Mod Pathol | 2015 | https://conductscience.org/library/papers/25431236 | PubMed |
| 17 | 23530101 | Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23530101 | PubMed |
| 18 | 23982601 | Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. | Br J Cancer | 2013 | https://conductscience.org/library/papers/23982601 | PubMed |
| 19 | 29276063 | Is sarcopenia and sarcopenic obesity associated with clinical and pathological outcomes in patients undergoing radical nephroureterectomy? | Urol Oncol | 2018 | https://conductscience.org/library/papers/29276063 | PubMed |
| 20 | 24037576 | Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. | Br J Surg | 2013 | https://conductscience.org/library/papers/24037576 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42223672 | Preclinical evaluation of rBCG-h12: an engineered Bacillus Calmette-Guérin with an enhanced activity against bladder and pancreatic cancers. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42223672 | PubMed |
| 41945867 | NQO1-Mediated Anoikis Resistance and Immune Evasion Define a High-Risk Multi-Omic Subtype for Precision Management of T1 High-Grade Bladder Cancer. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41945867 | PubMed |
| 40731936 | Sarcopenia in Urothelial Bladder Carcinoma: A Narrative Review. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40731936 | PubMed |
| 38999355 | Epirubicin and Non-Muscle Invasive Bladder Cancer Treatment: A Systematic Review. | J Clin Med | 2024 | https://conductscience.org/library/papers/38999355 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37101772
GET https://conductscience.org/api/papers/v1/37101772/references?page=2